Geneswell BCT is a precise and qualitative in vitro diagnostic test. The expression of 9 genes was obtained from the formalin fixed paraffin embedded block (FFPE) of breast cancer tissue samples by RT-qPCR, and the patients were divided into high-risk group and low-risk group.

This test provides prognostic information to assess the risk of recurrence. The BCT score calculated by geneswell BCT was associated with the risk of recurrence. The higher the BCT score, the more likely it is to relapse, and vice versa.

Inclusion Criteria:

• The patients were diagnosed with invasive breast cancer with positive hormone receptor (including positive estrogen receptor or progesterone receptor) and negative human epidermal growth factor receptor 2 (HER2)
• Axillary lymph node assessment : pN0 or PN1
• Women aged 18 and over
• Patients without chemotherapy after operation

Exclusion Criteria:

• Patients with negative hormone receptor （both estrogen and progesterone receptor are negative）
• Human epidermal growth factor receptor 2 （HER2） positive
• Pathological nodule evaluation: pN2 or pN3
• Male patients
• Patients receiving chemotherapy after surgery

Women with hormone receptor positive (estrogen, ER + or progesterone PR +, HER2 negative, and pN0 or PN1) early breast cancer